Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

multidrug resistant infections

- PMLiVE

AstraZeneca’s Calquence approved by EC for first-line chronic lymphocytic leukaemia use

An estimated 27,000 cases of the disease were diagnosed in the UK, France, Germany, Spain and Italy in 2024

- PMLiVE

Takeda receives EC approval for Adcetris combination in Hodgkin lymphoma

The decision marks the second approval for an Adcetris-based regimen for front-line Hodgkin lymphoma

- PMLiVE

AstraZeneca’s Forxiga recommended by NICE for wider chronic kidney disease use

An estimated 7.2 million people in the UK are living with the progressive condition

- PMLiVE

AstraZeneca receives CHMP recommendation for Imfinzi regimen in bladder cancer

More than 614,000 cases of bladder cancer are diagnosed globally every year

- PMLiVE

AstraZeneca shares late-stage results for Airsupra in mild asthma patients

More than ten million asthma exacerbations occur in the US every year

- PMLiVE

AstraZeneca announces positive phase 3 results for Imfinzi in high-risk bladder cancer

Around half of NMIBC patients are classed as being high-risk for disease progression or recurrence

- PMLiVE

BeiGene’s Tevimbra combination granted EC approval in small cell lung cancer

Approximately 15% of all lung cancer patients are diagnosed with the aggressive disease

- PMLiVE

AstraZeneca/Daiichi Sankyo share positive phase 3 results for Enhertu in early breast cancer

Around one in three patients with early-stage breast cancer are considered high risk

- PMLiVE

AstraZeneca’s Calquence approved by EC for first-line mantle cell lymphoma use

The drug is now the only BTK inhibitor to be approved in the EU for first-line MCL

- PMLiVE

AstraZeneca’s triple-combination COPD therapy shows promise in uncontrolled asthma

Up to 262 million people worldwide are affected by the chronic respiratory disease

- PMLiVE

AstraZeneca’s Calquence regimens recommended by CHMP for chronic lymphocytic leukaemia

It is hoped that the fixed-duration treatments will reduce the risk of adverse events and drug resistance

regeneron headquarters

Regeneron’s bispecific antibody Lynozyfic approved by EC to treat multiple myeloma

More than 35,000 new cases of the blood cancer are diagnosed in Europe every year

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links